SP down likely because overall Market is down.

MIAMI LAKES, Fla., May 23, 2013 /PRNewswire/ -- Fuse Science, Inc. (OTCQB: DROP) (www.fusescience.com) a consumer products and delivery technology company that is developing new, patent-pending technologies poised to redefine how consumers receive energy, medicines, vitamins and minerals is pleased to announce, in partnership with Macular Health, LLC, advances in the development of an AREDS2 Drop formulation to combat Age-Related Macular Degeneration ("AMD"). AMD is a medical condition which usually affects older adults and results in a loss of vision because of damage to the retina.

"We have been anxiously awaiting the results of the AREDS2 study, so that we could incorporate the findings into the new Macular Health Drop Formulation. The ideal Drop formulation is well underway and we expect to begin clinical testing in July," said Macular Health's Chief Executive officer, Jeffery McAnnally. "We believe this study paves the way for an even bigger relationship between Macular Health and Fuse Science."

Rest of PR: http://ir.stockpr.com/fusescience/company-news/detail/934/fuse-science-inc-and-macular-health-advance-commercial-development-of-areds2-drop-formulation